CoChat
Sign Up
Cited by 87

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies

Perelygina, Ludmila, Chen, Min-hsin, Suppiah, Suganthi, Adebayo, Adebola, Abernathy, Emily, Dorsey, Morna, Bercovitch, Lionel, Paris, Kenneth, White, Kevin P., Krol, Alfons, Dhossche, Julie, Torshin, Ivan Y., Saini, Natalie, Klimczak, Leszek J., Gordenin, Dmitry A., Zharkikh, Andrey, Plotkin, Stanley, Sullivan, Kathleen E., Icenogle, Joseph·2019·PLOS Pathogens
DOI 10.1371/journal.ppat.1008080PMC PMC6837625
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1008080

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recent analysis of SARS-CoV-2 and rubella vaccine virus genome data derived from patients show predominant mutational patterns with specific signatures rather than random genetic variations, suggesting that host-factor induced mutations play an important role in shaping the viral genomic RNA mutational outcome and evolution.

    “Recent analysis of SARS-CoV-2 and rubella vaccine virus genome data derived from patients show predominant mutational patterns with specific signatures rather than random genetic variations, suggesting that the host-factor induced mutations play an important role in shaping the viral genomic RNA mutational outcome and evolution11–14.”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [13]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 82

  1. WE Rawls, 1974, Viral persistence in congenital rubella, Prog Med Virol, 18, 273
  2. N Lambert, 2015, Rubella, Lancet
  3. FE Sherman, 1965, Acute encephalopathy (encephalitis) complicating rubella. Report of cases with virologic studies, cortisol-production determinations, and observations at autopsy, JAMA, 192, 675, 10.1001/jama.1965.03080210019005 · DOI
  4. EO Kreps, 2015, Fuchs' uveitis syndrome: no longer a syndrome?, Ocul Iammunol and Inflamm, 29, 1
  5. SA Plotkin, 2006, The history of rubella and rubella vaccination leading to elimination, Clin Infect Dis, 43, S164, 10.1086/505950 · DOI
  6. GB Grant, 2017, Progress in rubella and congenital rubella syndrome control and elimination—Worldwide, 2000–2016, MMWR Morb Mortal Wkly Rep, 66, 1256, 10.15585/mmwr.mm6645a4 · DOI
  7. AJ Tingle, 1997, Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women, Lancet, 349, 1277, 10.1016/S0140-6736(96)12031-6 · DOI
  8. SM Islam, 2000, Anterior uveitis following combined vaccination for measles, mumps and rubella (MMR): a report of two cases, Acta Ophthalmol Scand, 78, 590, 10.1034/j.1600-0420.2000.078005590.x · DOI
  9. S Plotkin, 2011, Infectious diseases of the fetus and newborn infant, 861, 10.1016/B978-1-4160-6400-8.00028-6 · DOI
  10. C Picard, 2018, International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity, J Clin Immunol, 38, 96, 10.1007/s10875-017-0464-9 · DOI
  11. WT Shearer, 2014, Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts, J Allergy Clin Immunol, 133, 961, 10.1016/j.jaci.2013.11.043 · DOI
  12. MM Eibl, 2015, Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities, Immunotherapy, 7, 1273, 10.2217/IMT.15.74 · DOI
  13. A Nanda, 2014, Noninfectious cutaneous granulomas in primary immunodeficiency disorders: report from a national registry, Am J Dermatopathol, 36, 832, 10.1097/DAD.0000000000000112 · DOI
  14. J Leung, 2018, Prevalence of granulomas in patients with primary immunodeficiency disorders, United States: Data From national health care claims and the US Immunodeficiency Network Registry, J Clin Immunol, 38, 717, 10.1007/s10875-018-0534-7 · DOI
  15. C Bodemer, 2014, Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency, Clin Microbiol Infect, 20, O656, 10.1111/1469-0691.12573 · DOI
  16. L Perelygina, 2016, Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies, J Allergy Clin Immunol, 138, 1436, 10.1016/j.jaci.2016.06.030 · DOI
  17. B Neven, 2017, Cutaneous and visceral chronic granulomatous disease triggered by a rubella virus vaccine strain in children with primary immunodeficiencies, Clin Infect Dis, 64, 83, 10.1093/cid/ciw675 · DOI
  18. D Buchbinder, 2019, Rubella virus-associated cutaneous granulomatous disease: a unique complication in immune-deficient patients, not limited to DNA repair disorders, J Clin Immunol
  19. SA Plotkin, 1969, Attenuation of RA 27–3 rubella virus in WI-38 human diploid cells, Am J Dis Child, 118, 178
  20. L Perelygina, 2015, Differences in establishment of persistence of vaccine and wild type rubella viruses in fetal endothelial cells, PLoS One, 10, e0133267, 10.1371/journal.pone.0133267 · DOI
  21. JA Gonzales, 2018, Association of ocular inflammation and rubella virus persistence, JAMA Ophthalmol
  22. Z Yang, 2000, Statistical methods for detecting molecular adaptation, Trends Ecol Evol, 15, 496, 10.1016/S0169-5347(00)01994-7 · DOI
  23. J Echave, 2016, Causes of evolutionary rate variation among protein sites, Nat Rev Genet, 17, 109, 10.1038/nrg.2015.18 · DOI
  24. Z Liu, 1996, Identification of domains in rubella virus genomic RNA and capsid protein necessary for specific interaction, J Virol, 70, 2184, 10.1128/JVI.70.4.2184-2190.1996 · DOI
  25. MH Chen, 2004, Rubella virus capsid protein modulates viral genome replication and virus infectivity, J Virol, 78, 4314, 10.1128/JVI.78.8.4314-4322.2004 · DOI
  26. CS Ilkow, 2011, The rubella virus capsid as an anti-apoptotic protein that attenuates the pore-forming ability of Bax, PLoS Pathog, 7, e1001291, 10.1371/journal.ppat.1001291 · DOI
  27. V Petit, 2009, Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo, J Mol Biol, 385, 65, 10.1016/j.jmb.2008.10.043 · DOI
  28. RS Harris, 2015, APOBECs and virus restriction, Virology, 479-480, 131, 10.1016/j.virol.2015.03.012 · DOI · Paper page
  29. S Tomaselli, 2015, ADARs and the balance game between virus infection and innate immune cell response, Curr Issues Mol Biol, 17, 37
  30. EW Refsland, 2013, The APOBEC3 family of retroelement restriction factors, Curr Top Microbiol Immunol, 371, 1
  31. A Niavarani, 2015, APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts, PLoS One, 10, e0120089, 10.1371/journal.pone.0120089 · DOI
  32. S Sharma, 2015, APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages, Nat Commun, 6, 6881, 10.1038/ncomms7881 · DOI · Paper page
  33. S Sharma, 2016, The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme, Sci Rep, 6, 39100, 10.1038/srep39100 · DOI · Paper page
  34. KM Prohaska, 2014, The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions, Wiley Interdiscip Rev RNA, 5, 493, 10.1002/wrna.1226 · DOI
  35. AG Lada, 2011, Mutator effects and mutation signatures of editing deaminases produced in bacteria and yeast, Biochemistry (Mosc), 76, 131, 10.1134/S0006297911010135 · DOI
  36. K Chan, 2015, An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers, Nat Genet, 47, 1067, 10.1038/ng.3378 · DOI · Paper page
  37. D Yang, 1998, Effects of mutations in the rubella virus E1 glycoprotein on E1-E2 interaction and membrane fusion activity, J Virol, 72, 8747, 10.1128/JVI.72.11.8747-8755.1998 · DOI
  38. H Cong, 2011, Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus, J Virol, 85, 11038, 10.1128/JVI.05398-11 · DOI
  39. L Ho-Terry, 1986, Immunological characterisation of the rubella E 1 glycoprotein. Brief report, Arch Virol, 90, 145, 10.1007/BF01314152 · DOI
  40. HH Chaye, 1992, Cellular and humoral immune responses to rubella virus structural proteins E1, E2, and C, J Clin Microbiol, 30, 2323, 10.1128/JCM.30.9.2323-2329.1992 · DOI
  41. JS Wolinsky, 1991, Monoclonal antibody-defined epitope map of expressed rubella virus protein domains, J Virol, 65, 3986, 10.1128/JVI.65.8.3986-3994.1991 · DOI
  42. KY Green, 1986, Rubella virus antigens: localization of epitopes involved in hemagglutination and neutralization by using monoclonal antibodies, J Virol, 57, 893, 10.1128/JVI.57.3.893-898.1986 · DOI
  43. AE Lovett, 1993, Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes, J Virol, 67, 5849, 10.1128/JVI.67.10.5849-5858.1993 · DOI
  44. D Ou, 1997, Characterization of an overlapping CD8+ and CD4+ T-cell epitope on rubella capsid protein, Virology, 235, 286, 10.1006/viro.1997.8704 · DOI
  45. RM DuBois, 2013, Functional and evolutionary insight from the crystal structure of rubella virus protein E1, Nature, 493, 552, 10.1038/nature11741 · DOI
  46. SA Plotkin, 1985, History of RA27/3 rubella vaccine, Rev Infect Dis, 7, S77, 10.1093/clinids/7.Supplement_1.S77 · DOI
  47. L Perelygina, 2013, Persistent infection of human fetal endothelial cells with rubella virus, PLoS One, 8, e73014, 10.1371/journal.pone.0073014 · DOI
  48. EE Seagle, 2018, Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine, Vaccine, 36, 818, 10.1016/j.vaccine.2017.12.075 · DOI · Paper page
  49. NP Miki, 1992, Differential ability of wild-type and vaccine strains of rubella virus to replicate and persist in human joint tissue, Clin Exp Rheumatol, 10, 3
  50. S Duffy, 2008, Rates of evolutionary change in viruses: patterns and determinants, Nat Rev Genet, 9, 267, 10.1038/nrg2323 · DOI
  51. Z Zhu, 2016, Analysis of complete genomes of the rubella virus genotypes 1E and 2B which circulated in China, 2000–2013, Sci Rep., 6, 39025, 10.1038/srep39025 · DOI
  52. E Domingo, 1998, Quasispecies structure and persistence of RNA viruses, Emerg Infect Dis, 4, 521, 10.3201/eid0404.980402 · DOI
  53. P Farci, 2000, The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies, Science, 288, 339, 10.1126/science.288.5464.339 · DOI
  54. P Lemey, 2006, HIV evolutionary dynamics within and among hosts, AIDS Rev, 8, 125
  55. J Raghwani, 2016, Exceptional heterogeneity in viral evolutionary dynamics characterises chronic hepatitis C virus infection, PLoS Pathog, 12, e1005894, 10.1371/journal.ppat.1005894 · DOI
  56. FA Koning, 2009, Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets, J Virol, 83, 9474, 10.1128/JVI.01089-09 · DOI
  57. Y Liu, 2015, Circulating type 1 vaccine-derived poliovirus may evolve under the pressure of adenosine deaminases acting on RNA, J Matern Fetal Neonatal Med, 28, 2096, 10.3109/14767058.2014.979147 · DOI
  58. M Fehrholz, 2012, The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses, J Gen Virol, 93, 565, 10.1099/vir.0.038919-0 · DOI
  59. A Milewska, 2018, APOBEC3-mediated restriction of RNA virus replication, Sci Rep, 8, 5960, 10.1038/s41598-018-24448-2 · DOI
  60. E Abernathy, 2013, Analysis of whole genome sequences of 16 strains of rubella virus from the United States, 1961–2009, Virol J., 10, 32, 10.1186/1743-422X-10-32 · DOI
  61. GM Schiff, 1963, Rubella virus: neutralizing antibody in commercial gamma globulin, Science, 142, 58, 10.1126/science.142.3588.58 · DOI
  62. JA Quiroga, 1995, Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome, Hepatology, 22, 1635, 10.1002/hep.1840220604 · DOI
  63. A Aghamohammadi, 2017, Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication, Front Immunol, 8, 685, 10.3389/fimmu.2017.00685 · DOI
  64. MJ Memoli, 2014, The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts, Clin Infect Dis, 58, 214, 10.1093/cid/cit725 · DOI
  65. KS Xue, 2017, Parallel evolution of influenza across multiple spatiotemporal scales, Elife, 6
  66. J Dhossche, 2019, Cutaneous Granulomatous Disease With Presence of Rubella Virus in Lesions, JAMA Dermatol
  67. L Perelygina, 2019, Outcomes for nitazoxanide treatment in a case series of patients with primary immunodeficiencies and rubella virus-associated granuloma, J Clin Immunol
  68. E Abernathy, 2009, Confirmation of rubella within 4 days of rash onset: comparison of rubella virus RNA detection in oral fluid with immunoglobulin M detection in serum or oral fluid, J Clin Microbiol, 47, 182, 10.1128/JCM.01231-08 · DOI
  69. P Namuwulya, 2014, Phylogenetic analysis of rubella viruses identified in Uganda, 2003–2012, J Med Virol
  70. MH Chen, 2007, An indirect immunocolorimetric assay to detect rubella virus infected cells, J Virol Methods, 146, 414, 10.1016/j.jviromet.2007.08.021 · DOI
  71. JS Rota, 2013, Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York city in 2009, Clin Vaccine Immunol., 20, 391, 10.1128/CVI.00660-12 · DOI
  72. KB Hummel, 1992, Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays, J Clin Microbiol, 30, 2874, 10.1128/JCM.30.11.2874-2880.1992 · DOI
  73. KB Hummel, 2006, Development of quantitative gene-specific real-time RT-PCR assays for the detection of measles virus in clinical specimens, J Virol Methods, 132, 166, 10.1016/j.jviromet.2005.10.006 · DOI
  74. 2005, Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses, Wkly Epidemiol Rec, 80, 126
  75. RC Edgar, 2004, MUSCLE: multiple sequence alignment with high accuracy and high throughput, Nucleic Acids Res, 32, 1792, 10.1093/nar/gkh340 · DOI · Paper page
  76. S Kumar, 2016, MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets, Mol Biol Evol, 33, 1870, 10.1093/molbev/msw054 · DOI
  77. M Nei, 1986, Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions, Mol Biol Evol, 3, 418
  78. B Korber, 2000, Computational analysis of HIV molecular sequences, 55
  79. K Jukes, 1969, Mammalian Protein Metabolism, 21, 10.1016/B978-1-4832-3211-9.50009-7 · DOI · Paper page
  80. IY Torshin, 2004, Computed energetics of nucleotides in spatial ribozyme structures: an accurate identification of functional regions from structure, ScientificWorldJournal, 4, 228, 10.1100/tsw.2004.19 · DOI
  81. I Patrusheva, 2016, B virus (Macacine Herpesvirus 1) divergence: variations in glycoprotein D from clinical and laboratory isolates diversify virus entry strategies, J Virol, 90, 9420, 10.1128/JVI.00799-16 · DOI
  82. JM Eggington, 2011, Predicting sites of ADAR editing in double-stranded RNA, Nat Commun, 2, 319, 10.1038/ncomms1324 · DOI

Cited by

Sorted by citations

Metadata

Authors
Perelygina, L., Chen, M.-H., Suppiah, S., Adebayo, A., Abernathy, E., Dorsey, M., Bercovitch, L., Paris, K., White, K. P., Krol, A., Dhossche, J., Torshin, I. Y., Saini, N., Klimczak, L. J., Gordenin, D. A., Zharkikh, A., Plotkin, S., Sullivan, K. E., & Icenogle, J.
ORCID
Venue
PLOS Pathogens
Publisher
Public Library of Science (PLoS)
Published
2019-10-28
Volume
15
Issue
10
Pages
e1008080
ISSN
1553-7374
DOI
10.1371/journal.ppat.1008080
PMC
PMC6837625
Cited by
87
References
2
Language
en
Update notices
new_version (2019-11-07)
Licence
creativecommons.org/publicdomain/zero/1.0/ (vor)
Funders
  • Centers for Disease Control and Prevention (core funding to rubella team)
  • US National Institute of Health (Z1AES103266, R21-AI130967-01A1)
  • Wallace Chair of Pediatrics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review